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Abstract
Background: Signal transducer and activator of transcription (STAT) activation of gene expression is both rapid
and transient, and when properly executed it affects growth, differentiation, homeostasis and the immune
response, but when dysregulated it contributes to human disease. Transcriptional activation is regulated by
alterations to the chromatin template. However, the role of histone modification at gene loci that are activated for
transcription in response to STAT signaling is poorly defined.
Results: Using chromatin immunoprecipitation, we profiled several histone modifications during STAT1 activation
of the interferon regulatory factor 1 gene (IRF1). Methylated lysine histone proteins H3K4me2, H3K4me3,
H3K79me3, H3K36me3 and monoubiquitinated histone ubH2B are dynamic and correlate with interferon (IFN)g
induction of STAT1 activity. Chemical inhibition of H3K4 methylation downregulates IRF1 transcription and
decreases RNA polymerase II (Pol II) occupancy at the IRF1 promoter. MEN1, a component of a complex proteins
associated with Set1 (COMPASS)-like complex and the hBRE1 component, RNF20, are localized to IRF1 in the
uninduced state and are further recruited when IRF1 is activated. RNAi-mediated depletion of RNF20 lowers both
ubH2B and H3K4me3, but surprisingly, upregulates IFNg induced IRF1 transcription. The dynamics of
phosphorylation in the C-terminal domain (CTD) of Pol II are disrupted during gene activation as well.
Conclusions: H2B monoubiquitination promotes H3K4 methylation, but the E3 ubiquitin ligase, RNF20, is repressive
of inducible transcription at the IRF1 gene locus, suggesting that ubH2B can, directly or indirectly, affect Pol II CTD
phosphorylation cycling to exert control on ongoing transcription.
Background
In response to a variety of extracellular ligands, signal
transducers and activators of transcription (STATs) are
rapidly recruited from their latent state in the cytoplasm
to cell surface receptors, where they are phosphorylated
by tyrosine kinases. They then translocate to the
nucleus, bind DNA response elements and drive the
transcription of target genes, affecting growth, differen-
tiation, homeostasis and the immune response [1]. Not
surprisingly, given their widespread involvement in
normal cellular processes, dysregulation of STAT activ-
ity contributes to human disease, particularly to cancers.
Persistently active STAT3 and STAT5 are present in
breast cancers, head and neck cancers, prostate cancers,
multiple myeloma, leukemias and lymphomas [2,3].
STAT activation is both rapid and transient, with the
downregulation of STAT activity achieved by several
mechanisms, including dephosphorylation by the 45-kDa
nuclear phosphatase T cell protein tyrosine phosphatase
(TC45), which inactivates the STATs by removing their
required tyrosine phosphates, and the cytoplasmic phos-
phatase Src homology region 2 domain-containing phos-
phatase-1 (SHP-1), which dephosphorylates the kinases
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upstream of STATs. Other negative regulators include
the suppressor of cytokine signaling (SOCS) family of
proteins, which are induced by cytokine signaling and
STAT activation and participate in a negative feedback
loop, and the protein inhibitor of activated STAT (PIAS)
family of proteins, which can directly inhibit STATs by
preventing their DNA binding [4].
Transcriptional activation, like that mediated by
STATs, is one of several nuclear processes regulated by
alterations to the chromatin fiber. Such alterations are
dynamic and include covalent histone modifications and
DNA methylation, as well as the activities of ATP-
dependent complexes [5]. Chromatin’s core structure,
the nucleosome, is composed of 146 bp of DNA
wrapped around an octamer of histone proteins (H3,
H4, H2A and H2B). A number of post-translational
modifications to the nucleosome, mostly in histone N-
terminal tails, have been described, including methyla-
tion, acetylation, phosphorylation and ubiquitination.
These covalent modifications define the functional state
of chromatin via both cis and trans mechanisms. Cis
mechanisms, best typified by acetylation/deacetylation,
result in changes to nucleosome packing that increase
or decrease DNA accessibility. In trans mechanisms,
non-histone proteins that possess particular binding
domains recognize specific histone modifications and
recruit additional factors that regulate chromatin struc-
ture [6,7]. Together, cis and trans mechanisms embellish
the chromatin fiber to generate biological effects that
extend beyond the DNA sequence alone.
Several genome-wide studies have investigated how
particular histone methylations correlate with gene
expression in human cells [8-14]. Dimethylation and tri-
methylation of lysine 4 (H3K4me2, H3K4me3) in the N-
terminal tail of histone H3 are known to correlate with
an active chromatin state. Trimethylation of lysine 27
(H3K27me3) is associated with silenced chromatin,
while monomethylation of this same residue is broadly
localized to euchromatin. H3K36me3 is enriched down-
stream of the promoters of actively transcribed genes,
and thus, is strongly correlated with H3K4me3, but is
not correlated at all with H3K27me3. H3K9me3 is typi-
cally associated with transcriptional repression, as is
H4K20me1 [15] although others have linked these mod-
ifications to the activation of some genes [9,16,17].
H3K79me3 is associated with actively transcribed genes
but Barski et al. found this modification is enriched at
some silent genes [9,18,19]. Such discrepancies suggest
that the function of histone methylation might be gene
specific and depend upon the recruitment of different
trans-acting complexes, or that methylation status might
be dynamic and titrated during gene expression by the
concerted activity of histone methyltransferases (HMTs)
and demethylases (HDMs) [20-23].
In mammalian cells, there are multiple H3K4 methyl-
transferases, including SET1A/B and mixed lineage leu-
kemia (MLL) proteins 1-4, which contribute to complex
proteins associated with Set1 (COMPASS) and COM-
PASS-like complexes, respectively [24]. WDR82, the
human homolog of Cps35/Swd2, is associated only with
SET1A/B complexes (not MLL1-4 complexes). Like
Cps35, WDR82 interacts with chromatin in a manner
that depends upon the monoubiquitination of H2B [25],
suggesting a mechanism similar to the crosstalk
mechanism that is well established in Saccharomyces
cerevisiae where H3K4 methylation requires H2B mono-
ubiquitination (ubH2B). Along these same lines, in vitro
transcription assays suggest that the presence of ubH2B
on chromatin stimulates SET1/COMPASS-dependent
H3K4 dimethylation and trimethylation [26]. It was
reported recently that ubH2B is associated with the
transcribed regions of highly expressed genes in human
cells. However, RNF20/BRE1A, a human homolog of the
yeast E3 ubiquitin ligase, Bre1, can both activate and
repress distinct subsets of genes [27,28].
While little is known about the role of histone modifi-
cation in regulating the activity of genes that are poised
for transcription in response to STAT signaling, the
rapid and transient nature of STAT-triggered transcrip-
tion makes it an attractive system in which to study
dynamic signaling to chromatin. Interferon (IFN)g acti-
vation of STAT1 drives higher order chromatin remo-
deling at the major histocompatability complex (MHC)
and correlates with recruitment of the chromatin-remo-
deling enzyme BRG and histone acetylation [29,30].
However, surprisingly, histone deacetylase activity is
reportedly required for the transcription of IFN-respon-
sive genes, but the mechanistic basis for this require-
ment is unknown [31,32].
Here we report the detailed profiling of the changes in
the histone modification landscape that accompany
STAT1-activated expression of the interferon regulatory
factor 1 gene (IRF1). To begin to address the molecular
basis for these changes, we identified a COMPASS-like
complex as the likely H3K4 methyltransferase associated
with the IRF1 promoter and showed that full H3K4 tri-
methylation depends upon the activity of the ubiquitina-
tion enzyme RNF20/BRE1A. Furthermore, our data
indicate that H2B monoubiquitination, located across
the IRF1 gene, represses transcription when STAT1 sig-
naling is induced by IFNg.
Results
Histone modifications correlate with inducible STAT1
activity
To investigate chromatin’s contribution to STAT-
induced gene expression, we generated a detailed profile
of the distribution of several histone modifications
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across the IRF1 gene locus in 2fTGH cells treated with
IFNg using chromatin immunoprecipitation (ChIP).
IFNg rapidly triggers IRF1 gene expression by activating
STAT1 homodimers via the Janus kinase (JAK)-STAT
signaling pathway. Therefore, a 2fTGH derived cell line,
termed U3A, that lacks STAT1 expression was used as
a negative control [33]. To assay for dynamic changes in
histone modification, we collected ChIP data before,
during and after STAT activation, having determined
that IRF1 gene expression peaked at approximately 90
min and dissipated within 5 h when cells were treated
with IFNg for 30 min and then returned to normal
growth media (Figure 1 and Additional file 1e).
Studies from several model systems have determined
that methylation of lysines 4, 36 and 79 of histone H3
are typically associated with active gene expression
[9,11,18,34]. Likewise, we found H3K4me2, H3K4me3,
H3K79me3 and H3K36me3 all increase in a manner
that parallels STAT1 activity (Figure 2). With the excep-
tion of H3K79me3, the location of these modifications
at the IRF1 locus is the same as reported in other stu-
dies [9,23]. H3K4me3 is located near the promoter, as is
H3K4me2, although the latter shows the considerably
broader peak typical for this modification (Figure 2c, d).
H3K4me2 and me3 are also present at significant levels
near the promoter in the uninduced state and in U3A
cells, as is RNA polymerase II (Pol II) (Figures 2 and 3),
confirming that IRF1, like most genes, undergoes tran-
scriptional initiation [8,23]. The sharp dip observed at
position -5 reflects the nucleosome depletion found at
transcription start sites (TSSs).
H3K79me3 overlaps with H3K4me2 but extends
further into the coding region, consistent with its
described association with transcriptional elongation
(Figure 2e) [19]. H3K79me3 is found only at very low
levels at the IRF1 gene in 2fTGH cells in the uninduced
state or in U3A cells (Figure 3). Thus, this modification
specifically correlates with STAT1-induced transcription.
This profile for H3K79me3, is different from the profile
reported in a genome-wide study of CD4+ T cells which
found H3K79me3 higher at silent promoters than at
active ones, except in a narrow region near the TSS [9].
As expected, H3K36me3 was found to be biased toward
the 3’ region of the gene and is associated with elonga-
tion (Figure 2f). The H3K36me3 profile differs from the
other profiles collected; specifically, this modification
returns to uninduced levels at 5 h post-IFNg treatment
suggesting that a demethylase may target H3K36. The
overall histone occupancy observed, determined using a
pan H3 antibody, was consistent across the IRF1 locus,
except at the TSS where a dip was observed as a result of
TSS histone depletion (Figure 2g).
To confirm the dynamic nature of histone modifica-
tion in STAT induced transcription, we performed ChIP
assays at three other IFNg responsive genes (RING4,
PSMB8, GBP1) with quantitative real-time PCR (Q-
PCR) primers designed to amplify the 5’, 3’ and middle
regions of these gene loci and found similar patterns
(data not shown). Taken together, the patterns and
dynamics of these histone modifications indicate that
STAT1 dependent genes experience transcription initia-
tion but that downstream events, dependent upon
STAT1’s activation and DNA binding, regulate the accu-
mulation of transcripts.
Inhibition of methyltransferase activity decreases
H3K4me3 and H3K36me3 at the IRF1 gene as well as IRF1
transcription
Next, we investigated whether the pharmacological drug,
5’-deoxy-5’-methyl-thioadenosine (MTA), which inhibits
protein and DNA methylation, altered the dynamic
changes in histone methylation observed at the IRF1
gene in response to IFNg [35,36] Previously, MTA treat-
ment had been shown to reduce the global levels of
H3K4me3 by approximately twofold in HeLa cells, and
to specifically reduce H3K4me3 but not H3K4me2 levels
in the genome of HSV-1 during lytic infection [36].
Similarly, we observed that induced H3K4me3 levels
were reduced by treatment with MTA, and that
H3K4me2 remained unchanged (Figure 4a, b). However,
the global levels of H3 lysine 4 methylation were not
detectably lowered suggesting that the turnover of these
modifications in 2fTGH cells is slower than in HeLa
cells (Additional file 1a, b). We also examined the effect
of MTA treatment on inducible H3K36me3 levels and
Figure 1 Time course of interferon regulatory factor 1 gene
(IRF1) expression in response to interferon (IFN)g treatment.
2fTGH cells were treated with IFNg (5 ng/ml) for 30 min and then
returned to normal growth media. Reverse transcription quantitative
PCR (RT Q-PCR) was performed after the times shown to quantitate
IRF1 expression relative to glyceraldehyde 3-phosphate
dehydrogenase gene (GAPDH) expression, and presented as fold
change upon induction. Error bars represent standard error (n = 3).
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Figure 2 Histone H3 lysine methylation across the interferon regulatory factor 1 gene (IRF1) locus is dynamic in response to
interferon (IFN)g induction. (a-g) Chromatin immunoprecipitation (ChIP) of 2fTGH cells treated with IFNg for 30 min, or uninduced, and then
collected at various time points. The indicated antibodies were used and quantitative PCR (Q-PCR) quantified the precipitate yield, reported as
percentage of input. IgG served as the negative control and Pan H3 antibody as the positive control and indicator of histone levels across IRF1
(g). Locations of Q-PCR primers designed to span the entire locus of IRF1 are shown in (h).
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found that they were decreased as well (Figure 4c). This
is not surprising, given that MTA is a general methyl-
transferase inhibitor. (The ChIP-grade antibody used to
immunoprecipitate H3K79me3 in Figure 2 was discon-
tinued and so we were unable to follow up our studies
of this modification.)
MTA has also been shown to decrease HSV-1 gene
transcription during lytic infection [36]. Therefore, we
considered if the decreases we observed for H3K4me3
and H3K36me3 correlated with decreased transcription
of the IRF1 gene using reverse transcriptase followed by
Q-PCR. Indeed, an approximately twofold reduction in
the steady-state level of IRF1 mRNA was observed (Fig-
ure 4d). We confirmed that the reduction was due to
decreased transcription by quantitating the IRF1 tran-
script levels in heterogeneous nuclear RNA (hnRNA)
Figure 3 Histone H3 lysine methylation is present across the interferon regulatory factor 1 gene (IRF1) locus but is not dynamic in
signal transducer and activator of transcription 1 (STAT1)-null cells. (a-e) Chromatin immunoprecipitation (ChIP) of U3A cells treated with
interferon (IFN)g for 30 min, or uninduced, and then collected at various time points. The indicated antibodies were used and quantitative PCR
(Q-PCR) quantified the precipitate yield, reported as percentage of input. IgG served as the negative control. Locations of Q-PCR primers
designed to span the entire locus of IRF1 are shown as in Figure 2h.
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using PCR primers that target intronic sequences (Fig-
ure 4e) [37]. STAT1 occupancy was not altered by
MTA treatment, but Pol II occupancy at the TSS was
decreased (Figure 4g, h).
H2B monoubiquitination
In yeast, H3 K4 methylation depends upon H2B monou-
biquitination [38]. In order to investigate the role of
H2B ubiquitination in STAT1-induced transcription, we
first determined the profile of ubH2B at the IRF1 locus
at different times of IFNg induction in 2fTGH cells (Fig-
ure 5a) and in U3A cells (Figure 5b). ubH2B quickly
increases in response to IFNg, but decreases at later
time points. ubH2B is found highest in the middle cod-
ing region and lowest in the 5’ and 3’ regions. This pro-
file is identical to the ubH2B profile described in other
recent reports of mammalian cells, and the transient
nature is similar to an observation that has been
Figure 4 Dynamic H3 lysine methylation at the activated interferon regulatory factor 1 gene (IRF1) and IRF1 transcription are altered
by 5’-deoxy-5’-methyl-thioadenosine (MTA) treatment. 2fTGH cells treated with MTA (1.5 mM) or dimethylsulfoxide (DMSO) for 24 h
followed by treatment with interferon (IFN)g for 30 min. (a-c) Chromatin immunoprecipitation (ChIP) using the indicated antibodies. Data were
normalized to Pan H3 cycle threshold (Ct) values to account for a non-specific carrier (DMSO) effect and reported as percentage of input. (d, e)
Reverse transcription quantitative PCR (RT Q-PCR) was performed after the times shown to quantitate IRF1 mRNA and pre-mRNA expression
relative to glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH) expression and presented as fold change upon induction. Error bars
represent standard error (n = 3). **P = 0.01, *P = 0.05. (f) Arrows indicate locations of Q-PCR primers designed to amplify either exonic (d) or
intronic (e) regions of the IRF1 gene. (g, h) RNA polymerase II (Pol II) and signal transducer and activator of transcription 1 (STAT1) ChIP of
2fTGH cells.
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reported in the open reading frame (ORF) of the yeast
GAL1 gene [26,27,39]. In U3A cells, ubH2B is also asso-
ciated with the middle region of the gene, though at
very low levels (Figure 5b). In fact, we recovered all
assayed modifications (except perhaps H3K79me3) in
the uninduced state and in the STAT1-null cell line
(Figures 2 and 3). Thus, maintenance of these histone
modifications does not depend upon the induction of
IFNg responsive genes. Their maintenance could be
related to either basal transcription or a transcription-
independent mechanism or some combination of both.
Regardless, the observation of these modifications in
uninduced cells and U3A cells agrees with other reports,
and likely reflects how inducible genes are maintained in
a repressed but poised state [8,23].
RNF20 and a MLL/Menin complex are localized to IRF1
Having observed that both H2B monoubiquitination and
H3K4 methylation are dynamic during IRF1 gene expres-
sion, we next asked if the enzymes driving these histone
modifications are associated with or recruited to the IRF1
gene as a result of IFNg induction. A ChIP-grade anti-
body was used to immunoprecipitate RNF20 from chro-
matin collected from cells in both the uninduced and
induced state (Figure 6a). In response to IFNg, RNF20
accumulated across the IRF1 gene locus, beginning at
around +250 bp, which is where ubH2B also begins to
accumulate. Low levels of RNF20 were localized across
the IRF1 gene in the uninduced state as well, suggesting
that it might play a role in basal transcription.
There are several recognized H3K4 methyltransferases
in mammalian systems, including SET1A/B and MLL1-4
[40]. However, ChIP-grade antibodies that discriminate
among all of them are not available. Because the non-
enzymatic proteins that contribute to COMPASS and
COMPASS-like complexes do show some specificity, we
used a ChIP-grade antibody against Menin (MEN1),
which is a component unique to the MLL1 and MLL2
COMPASS-like complexes. ChIP assays showed that
MEN1 is constitutively associated with the IRF1 promo-
ter and that induction leads to an increase in a MEN1-
containing complex (Figure 6b). The COMPASS-like
activity constitutively associated with the IRF1 promoter,
potentially explains the significant amounts of H3K4
methylation observed in uninduced cells and even in
U3A cells (Figures 2 and 3).
RNAi-mediated knockdown of RNF20 upregulates IRF1
transcription
Having observed that RNF20 was recruited to IRF1 by
IFNg induction, we initially hypothesized that RNAi-
mediated knockdown of RNF20 would lower or prevent
IRF1 expression. Stable transfection of 2fTGH cells with
pGIPZ small hairpin RNA (shRNA)-RNF20 reduced the
endogenous expression of RNF20 by 98% (Figure 7c).
However, we consistently observed increased inducible
transcription in shRNA-RNF20 cells compared to a cell
line stably transfected with a non-silencing construct
(Figure 7a). We confirmed that the increased IRF1
mRNA accumulation was due to increased transcription
using intronic primers (Figure 7b). When an RNF20
cDNA that is C-terminally FLAG tagged was transiently
overexpressed (40%, Figure 7d) in 2fTGH cells, the
opposite effect on activated IRF1 transcription was
observed (Figure 7e).
H2B monoubiquitination and H3 lysine methylation
RNF20 knockdown diminished ubH2B during induction
of the IRF1 gene (Figure 8a). Importantly, inducible
H3K4me3 was lost as well (Figure 8b), providing sup-
port for a crosstalk mechanism in which H2B monoubi-
quitination promotes H3K4 methylation, as has been
described in other systems previously [38]. RNF20
knockdown did not affect H2K4me2 in any condition
Figure 5 H2B monoubiquitination is dynamic during interferon
regulatory factor 1 gene (IRF1) induction. Chromatin
immunoprecipitation (ChIP), using ubH2B antibody, of 2fTGH cells
(a) or U3A cells (b) treated with interferon (IFN)g for 30 min and
collected after the various time points. IgG served as the negative
control. Locations of quantitative PCR (Q-PCR) primers designed to
span the entire locus of IRF1 are as in Figure 2h.
Figure 6 RNF20 and MEN1 are constitutively associated with
the interferon regulatory factor 1 gene (IRF1) and recruited by
interferon (IFN)g induction. 2fTGH cells were induced with IFNg for
30 min or uninduced. Chromatin immunoprecipitation (ChIP) was
performed using antibodies against RNF20 (a) and MEN1 (b) and
quantitative PCR (Q-PCR) quantified the precipitate yield, reported as
percentage of input. MEN1 was not detectable using primer pairs
beyond 3,000 bp.
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Figure 7 RNAi-mediated RNF20 knockdown increases interferon regulatory factor 1 gene (IRF1) transcription. (a, b) Reverse transcription
quantitative PCR (RT Q-PCR) to quantitate IRF1 mRNA and pre-mRNA expression in stably selected 2fTGH cells expressing a non-silencing small
hairpin (sh)RNA or RNF20-shRNA that were uninduced or treated with IFNg. IRF1 expression was normalized to ACTB and presented as fold
change relative to the uninduced, non-silencing shRNA condition. Error bars are standard error (n = 4). (c) Western blot of extracts prepared
from stably selected 2fTGH cells expressing non-silencing shRNA (NS) or RNF20 shRNA or non-transfected cells (NT) with a-RNF20. Signal
transducer and activator of transcription 1 (STAT1) served as loading control. (d) Western blot of extracts prepared from transiently transfected
2fTGH cells expressing pcDNA3.0 or FLAG tagged RNF20 pcDNA3.0 with a-FLAG and a-RNF20. STAT1 served as loading control. (e) RT Q-PCR of
transiently transfected 2fTGH cells expressing pcDNA3.0 or FLAG tagged RNF20 pcDNA3.0 as in (a). Error bars are standard error (n = 2). **P =
0.01, *P = 0.05. Blot quantifications were performed using ImageJ.
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Figure 8 RNAi-mediated RNF20 knockdown prevents inducible ubH2B and H3K4me3. (a-l) Chromatin immunoprecipitation (ChIP) using
the indicated antibodies of stably selected 2fTGH cells expressing a non-silencing shRNA or shRNA-RNF20 after induction with interferon (IFN)g or
uninduced. Except for MEN1 (k), there were no statistically significant differences in any of the uninduced ChIP assays.
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(data not shown) and the uninduced levels of ubH2B,
H3K4me3 were also unchanged in the shRNA-RNF20
cell line compared to the non-silencing control cell line
(Figure 8g, h). H3K36me3 showed the same profiles in
both the induced and uninduced conditions (Figure 8c,
i). Pol II, MEN1 and STAT1 are recruited properly in
response to IFNg in these cell lines (Figure 8d-f),
although MEN1 does appear to acquire an increased
stability or association in the uninduced state in the
shRNA-RNF20 cell line (Figure 8k), but this enhanced
association does not correlate with increased H3K4me3
(Figure 8h). The RNF20 knockdown achieved in this cell
line is insufficient to fully ablate ubH2B; western blot-
ting demonstrated that there was an approximately 65%
loss of global ubH2B in the shRNA-RNF20 cell line
(Additional file 1c). An alternative explanation is that
hBRE1 is not the only H2B ubiquitinase in 2fTGH cells,
although this is unlikely [26].
Supportive of a crosstalk mechanism where ubH2B
promotes H3K4 methylation, we note that inhibition of
H2B ubiquitination using carbobenzoxy-L-leucyl-L-leu-
cyl-L-leucinal (MG132), a proteosome inhibitor that has
been used to rapidly and efficiently deplete ubH2B
[27,41], correlated with loss of both H3K4me3 and
H3K4me2 (Additional file 2b, c) in response to IFNg,
while H3K36me3 was unaffected (Additional file 2d).
When 2fTGH cells were treated with MG132, ubH2B
was eliminated globally (Additional file 1d), and at the
IRF1 gene locus when cells were induced with IFNg
(Additional file 2a).
Genetic studies in yeast and mammalian in vitro tran-
scription assays have demonstrated that H2B monoubi-
quitination depends upon the early steps of
transcriptional elongation, requiring the presence of the
polymerase associated factor (PAF) complex and the
addition of nucleoside triphosphates (NTPs), and not
simply recruitment of Rad6/Bre1 [26,38]. To find out if
ubH2B at the IRF1 gene also depends upon elongation,
2fTGH cells were treated with the elongation inhibitor
5,6-dichlorobenzimidazole riboside (DRB) [16,23]. Pol II
promoter occupancy is unaffected by DRB treatment
[18]. We confirmed that DRB ablates IRF1 induced gene
expression. (Additional file 3a) and it also significantly
inhibits basal transcription. In ChIP assays, in the DRB
treated condition, induced ubH2B was strongly
decreased, as was H3K4me3 (Additional file 3b, c).
H3K36me3 normally correlates with ongoing transcrip-
tion and so, not surprisingly, induced H3K36me3 was
also decreased by DRB (Additional file 3d).
RNAi-mediated knockdown of RNF20 alters Pol II C-
terminal domain (CTD) phosphorylation
In yeast, H2B ubiquitination has been functionally tied
to transcriptional elongation; H2B ubiquitination/
deubiquitination occurs dynamically, with deubiquitina-
tion required for the recruitment of the RNA polymer-
ase II CTD serine 2 kinase, Ctk1[39,42]. Additionally,
H3K4 methylation has been attributed a repressive role
at the GAL10-GAL1 locus [43]. H3K4me2/3 occurs via
cryptic transcription and recruits a histone deacetylase
(HDAC) activity (Rpd3) to dampen GAL1 promoter
activity by inhibiting Pol II recruitment. In the absence
of H3K4 methylation, GAL1 induction is accelerated.
Because H2B monoubiquitination is transient and
peaks prior to maximal IRF1 transcription (Figure 5a),
which occurs at approximately 90 min, and RNF20
depletion upregulates IRF1 while decreasing H3K4me3,
we speculated that RNF20 might directly or indirectly,
affect the recruitment of Pol II and/or the dynamics of
the phosphorylation that occurs at the CTD of Pol II
during transcription. As Pol II moves across a locus, a
change in phosphorylation occurs in the repeated
sequence, YSPTSPS, in the CTD of Pol II; serine 5 is
phosphorylated at initiation, while serine 2 phosphoryla-
tion is added during elongation [44,45]. ChIP assays
using antibodies that recognize total Pol II, serine 2
phosphorylation and serine 5 phosphorylation in the
CTD were performed using chromatin harvested at dif-
ferent times of IRF1 gene activation (Figure 9). The total
Pol II levels change as expected, increasing early in gene
induction and decreasing as transcription wanes at the
later time point, but with no differences in the shRNA-
RNF20 cell line versus the non-silencing cell line (Figure
9a, b). Phosphoserine 5 Pol II and phosphoserine 2 Pol
II also behave identically in the two cell lines at 30 min
of IFNg induction and in the uninduced condition (Fig-
ure 9c-f). However, at the later time point, both phos-
phoserine 5 Pol II and phosphoserine 2 Pol II in the
RNF20 depleted cell line remain high and do not return
to the lower levels seen in the control cell line (Figure
9d, f). Based on these data, we suspect that the increase
in transcription in the RNF20 depleted cells is mainly
the result of loss of a repressive effect from ubH2B.
Were the observed increase in transcription due to an
H3K4me2/3 based mechanism, Pol II and phosphoserine
5 Pol II should have been enriched at 30 min and/or in
the basal state. One possibility, among many, is that
ubH2B, in addition to determining the accessibility of a
serine 2 kinase (positive transcription elongation factor
b (P-TEFb)) to Pol II to foster elongation, also deter-
mines the accessibility of the phosphatases that target
serine 2 and/or 5. The result is a defect in Pol II CTD
cycling that acts to promote ongoing transcription.
Discussion
In this study, we characterized several histone modifica-
tions in STAT1 activation of the IRF1 gene and showed
that ubH2B promotes H3K4me3 during induction.
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Figure 9 RNA polymerase II (Pol II) C-terminal domain (CTD) serine phosphorylation in signal transducer and activator of transcription
1 (STAT1)-activated interferon regulatory factor 1 gene (IRF1) transcription is altered by RNF20 knockdown. Chromatin
immunoprecipitation (ChIP) of stably selected 2fTGH cells expressing a non-silencing small hairpin (shRNA) or shRNA-RNF20 after induction with
interferon (IFN)g or uninduced using antibodies specific for total Pol II (a, b), the serine 5 phosphorylated CTD of Pol II (c, d) and the serine 2
phosphorylated CTD of Pol II (e, f). The same results are seen when the data are normalized to total Pol II.
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Additionally, the enzymatic activities that produce these
modifications, COMPASS-like and RNF20, are found at
the IRF1 gene and are further recruited by induction.
These data, along with the observation that methyltrans-
ferase inhibition hinders IRF1 transcription, suggested a
positive regulatory role for these enzymes. Unexpectedly,
the E3 ligase that targets H2B for ubiquitination, RNF20,
acts as a repressor of transcription, ostensibly by altering
the dynamic phosphorylation of the CTD of Pol II that
determines its initiation, elongation and termination.
Mammalian ubH2B function
Other studies of ubH2B in inducible mammalian gene
expression have suggested alternative roles for this mod-
ification, than the repressive role our data indicates.
Using in vitro transcription assays with a recombinant,
fully H2B-ubiquitinated chromatin template, Kim et al.
observed that H2B ubiquitination does not affect p53
activated transcription, arguing that H2B ubiquitination
is a consequence of transcription and it does not
directly affect the function of the transcriptional
machinery [26]. In contrast, ubH2B reportedly enhances
the rate of transcriptional elongation by Pol II in
response to retinoic acid [46], and at HOX genes [47].
The dynamics of H2B ubiquitination during transcrip-
tional activation (Figure 5) and the observation that
RNF20 knockdown increases inducible IRF1 transcrip-
tion (Figure 7a, b), while its overexpression inhibits IRF1
(Figure 7e) all argue against the ideas that this modifica-
tion occurs in the wake of Pol II or promotes Pol II pas-
sage at the IRF1 gene. It is possible that these disparities
are simply related to the use of in vitro assays that dif-
ferently or incompletely recapitulate the inducible tran-
scription that occurs in vivo. Alternatively, the function
of ubH2B in gene expression might be context
dependent.
RNF20 as repressor in mammalian gene expression
Using gene expression microarrays, Shema et al. identi-
fied two cohorts of genes that are selectively up or
downregulated by RNF20 depletion in HeLa cells [28].
Based on our results, we speculate that these two
cohorts of genes may have different barriers built into
their chromatin, which contribute to regulation of their
expression. For instance, the cohort of genes that is acti-
vated by RNF20, such as TP53 and the HOX genes
[28,47] may not require a repressive mechanism to be
generated by ubH2B to regulate their transcription and,
in those cases, ubH2B works to promote elongation.
However, genes normally suppressed by RNF20 are
likely to be poised for activation and undergo basal tran-
scription, and therefore rely on H2B monoubiquitination
as a check against inappropriately activated transcrip-
tion. It is worth noting that Shema et al. report that this
later cohort of genes is populated by several early
response and proliferative genes, is enriched in Pol II
and H3K4me3 (as is IRF1) as compared to RNF20
dependent and independent genes, and that many are
constitutively ‘on’ but in a ‘low gear’ state, reflecting the
unique features of these genes that poise them for rapid
activation in response to signaling events.
Similarities to activated transcription at the GAL1 gene in
Saccharomyces cerevisiae
The role of histone modification in inducible gene
expression is best characterized at the GAL1 locus in
Saccharomyces cerevisiae [38]. At that gene, dimethyla-
tion and trimethylation of histone H3K4 depend upon
monoubiquitination of H2B (ubH2B) at K123 in a
mechanism involving the Rad6/Bre1 ubiquitination
enzymes and the Set1/COMPASS methyltransferase
complex [40]. While the precise mechanism for this
trans-tail communication is not fully established, a
model has emerged whereby the H2B ubiquitin ligase,
Bre1, and the E2 ubiquitin conjugase, Rad6, are
recruited to promoters by interaction with activators,
such as Gal4 [38]. The enzymatic activity for the mono-
ubiquitination of H2B, however, depends on further
interactions with the PAF complex, the Bur complex
and the phosphorylation of the CTD of Pol II at serine
5. H2B ubiquitination then recruits Cps35, (aka Swd2)
an essential component of COMPASS, which leads to
H3K4 dimethylation and trimethylation by the methyl-
transferase, Set1 [42,48-51]. H3K4me3 recruits the
SAGA complex, which contains the deubiquitinase,
Ubp8. Deubiquitination of ubH2B allows Ctk1 to phos-
phorylate the CTD of Pol II at serine 2, which in turn
recruits the methyltransferase for H3K36, Set2 [39].
Thus, Ubp8 provides the opposing deubiquitinase activ-
ity that is required for transition to efficient transcrip-
tional elongation at the inducible GAL1 gene. ubH2B’s
transitory profile at the IRF1 gene indicates that it
might be removed by an opposing ubiquitin hydrolase,
as it is in yeast. While other events, such as histone
exchange or direct or indirect RNF20 inactivation, are
also possible, studies in the lab are ongoing to deter-
mine if USP22 (the mammalian homolog to Ubp8) also
deubiquitinates ubH2B. It seems a likely possibility it
does, since USP22 is required for MYC activated tran-
scription [52], but whether ubH2B directly blocks
recruitment of a kinase (P-TEFb) responsible for serine
2 phosphorylation in CTD of Pol II is not known [53].
Several other important research questions are sug-
gested by the data presented here. First, what is the
mechanistic basis for the defect observed in Pol II CTD
phosphorylation cycling and is this the direct cause of
increased transcription observed in the RNF20 depleted
cell line? Might H2B monoubiquitination also impact
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the function of CTD phosphatases (Fcp1 and Rtr1) as it
does the kinase (Ctk1) across gene loci [54]? Second,
what is the basis for RFN20’s recruitment? Does STAT1
help to recruit hBRE1, as Gal4 and p53 do [38,55]?
What is the role of the PAF complex? And what is the
precise nature of the MEN1-containing, COMPASS-like
complex and which of its components functions as the
translator in the crosstalk with hRAD6/hBRE1? WDR82
mediates the crosstalk between hSET1/COMPASS and
the ubiquitination complex, but it is a component speci-
fic to hSET1 [25]. While we cannot rule out the possibi-
lity that SET1/COMPASS, or another H3K4
methyltransferase, is also involved redundantly, the colo-
calization of MEN1 and RNF20 at the IRF1 gene is the
first evidence of a possible interaction between COM-
PASS-like and hBRE1 in mammalian gene expression.
A different role for H3K36me3
Of the several histone modifications we profiled in this
study, only ubH2B and H3K36me3 return to basal
levels, mirroring the dynamics of STAT1 activation (Fig-
ures 2a, f and 5a) and IRF1 transcription (Figure 1). In
yeast, H2B deubiquitination drives H3K36me2, which
then works to prevent cryptic transcription by Pol II in
the 3’ end of genes by recruiting a histone deacetylase
[56-58]. In addition, H3K36me2 levels do not parallel
transcriptional output in a titratable fashion, but rather
reflect one of two states: uninduced/basal transcription
or induced transcription [59,60]. We, and Edmonds et
al. [23], observed this same profile for H3K36me3 at
inducible genes in mammalian cell lines. However,
mammalian H3K36me1/me2 levels are very low, and
deletion of the Set2 homolog responsible for
H3K36me3, SETD2, removes all H3K36me3, but with
no consequence for proper transcription, leading
Edmunds et al. to conclude that K36 methylation in
mammalian transcription does not mirror its role in
yeast. Our data support this conclusion, given that
forced H2B deubiquitination, achieved with MG132 and
RNF20 knockdown, did not alter H3K36me3.
While it is not yet clear what H3K36me3 contributes
to mammalian inducible gene expression, recent
research has revealed that H3K36me3 preferentially
marks exons relative to introns and it has been pro-
posed that H3K36me3 exon marking connects transcrip-
tion and splicing [61,62]. While the primer pairs used to
profile the IRF1 gene were designed without considering
intron-exon structure, the exons are heavily biased to
the 3’ end in the IRF1 gene (Figure 2h). The 3’ bias
observed for H3K36me3 may reflect this.
Conclusions
Signal transduction pathways, like the JAK-STAT path-
way, relay signals from the extracellular environment
through the cytoplasm and ultimately to the DNA, which
is organized as chromatin in the nucleus. Chromatin then
serves as the template for dynamic nuclear signaling
events (that is, post-translational modifications of his-
tones) that regulate transcription. These dynamic signaling
events are highly integrated, and it is becoming more clear
that it is the proper balance between opposing enzymatic
activities (E3 ubiquitin ligase/ubiquitin hydrolase, HMT/
HDM, kinase/phosphatase and so on) that determine the
functional output of a histone modification as either acti-
vating or repressing [63]. Therefore, it is important to bet-
ter define the function of histone modifications and the
interplay among the enzymatic activities (COMPASS-like,
hBRE1, PAF1 complex, USP22, and so on) that promote
these modifications if we are to fully understand how
chromatin contributes to both normal and aberrant acti-
vated transcription in mammalian systems.
Methods
Antibodies
The antibodies used were as follows: H3K4me3 (Abcam,
Cambridge, MA, USA, ab8580), H3K4me2 (Millipore,
Billerica, MA, USA, 07-030), H3K36me3 (Abcam
ab9050), H3K79me3 (Abcam ab2621), Pan H3 CT
(Millipore 07-690), ubH2B (Medimabs, Quebec, Canada,
MM-0029-p), RNA Pol II (Santa Cruz, Santa Cruz, CA,
USA sc-899), RNA polymerase II CTD repeat YSPTSPS
(phospho S2) (Abcam ab5095), RNA polymerase II CTD
repeat YSPTSPS (phospho S5) (Abcam ab5131), IgG
(Jackson Immunoresearch, West Grove, PA, USA),
STAT1 (Santa Cruz sc-345X), phospho-STAT1 (Tyr701)
(Cell Signaling Technology, Danvers, MA, USA, 9171S),
Menin (Bethyl Laboratories, Montgomery, TX, USA,
A300-105A), RNF20 (Abcam ab70495), RNF20-ChIP-
grade (Novus Biologicals, Littleton, CO, USA, NB100-
2242), FLAG (Sigma), Anti-rabbit or anti-mouse horse-
radish peroxidase (HRP) (Jackson Immunoresearch).
Cell lines and chemical inhibitors
2fTGH and U3A cell lines were cultured in HyClone
Dulbecco’s modified Eagle medium (DMEM)/high glu-
cose media supplemented with 10% cosmic calf serum
and 10% antibiotic/antimycotic (Fisher Scientific, Pitts-
burgh, PA, USA). Interferon (IFN)g treatment in all
cases involved adding IFNg (R&D Systems, Minneapolis,
MN, USA, 5 ng/ml) to the media for 30 min, replacing
with fresh media and harvesting cells at the indicated
times. MTA (Sigma, St. Louis, MO, USA), MG132 (Cal-
biochem, San Diego, CA, USA), DRB (Sigma) treated
cells were prepared as indicated in the figure legends.
Reverse transcriptase Q-PCR
Total RNA was collected using Isol-RNA lysis reagent (5
Prime, Gaithersburg, MD, USA). RNA was DNaseI
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(Invitrogen, Carlsbad, CA, USA) treated and phenol/
chloroform extracted. RNA (2 μg) was converted to
cDNA using the High Capacity RNA-to-cDNA kit
(Applied Biosystems, Carlsbad, CA, USA). cDNA was
then subjected to Q-PCR (Sybr Green, 7500 FAST Real
Time PCR System, Applied Biosystems) using gene spe-
cific primers to the intronic or exonic region of the
IRF1 gene. In all cases, an RT(-) control confirmed no
DNA contamination. Primer sequences will be provided
upon request. PCR efficiency was determined for all pri-
mer pairs before their use. To ensure the statistical sig-
nificance of differences reported in the RT-Q-PCR
assays, standard errors were calculated for the multipli-
cates, and when SE bars did not overlap, a paired t test
confirmed significance, P ≤ 0.05.
Western blot analysis
Cells were collected after various treatments and whole
cell extract, prepared as described in [64], was subjected
to SDS-PAGE (30 μg) and transferred to a nitrocellulose
membrane. Immunodetection was performed using anti-
pan H3 CT (1:25,000), anti-ubH2B (1:1,000), anti-
H3K4me3 (1:500), anti-H3K4me2 (1:5,000), anti-RNF20
(1:5,000), anti-STAT1 (1:1,000), anti-pY-STAT1
(1:1,000). A HRP anti-species secondary antibody
(1:10,000) was then applied and immunoreactive pro-
teins were visualized using chemiluminescence reagent
(Thermo Scientific, Pittsburgh, PA, USA). Histone acid
extraction was carried out as described previously [65].
Bands were quantified with ImageJ.
ChIP
ChIP was performed as described previously [66]. Briefly,
1 × 107 cells were fixed in 1% formaldehyde for 10 min
followed by the addition of 0.125 M glycine. Cells were
lysed using a douncer and the fixed chromatin was
sheared by sonication. Chromatin was subject to centri-
fugation (13,000 rpm for 25 min at 4°C) and was then
incubated overnight with various antibodies. Pan H3 and
IgG were included in all ChIPs as positive and negative
controls. Immunoprecipitation was carried out with pro-
tein A agarose/salmon sperm beads (Millipore). After
washing, the chromatin was eluted from the beads and
the cross links were reversed by heating at 65°C over-
night. DNA was treated with RNase A and proteinase K
(5 Prime), purified via phenol/chloroform extraction,
precipitated with ethanol overnight and resuspended in
TE buffer. Samples were analyzed by quantitative real
time-PCR (Applied Biosystems) using gene specific pri-
mers designed to run the length of the IRF1 gene. Primer
sequences provided upon request. PCR efficiency was
determined for all primer pairs before their use. Data are
expressed as percentage of input and all experiments
were performed in duplicate, if not triplicate. Where
indicated the data were normalized to the Pan H3 levels.
To ensure the statistical significance of differences
reported in the ChIP assays, standard errors were calcu-
lated for the multiplicates and, if necessary, a paired t
test confirmed significance, P ≤ 0.05.
Transfection of shRNAmir and expression vectors
A pGIPZ shRNAmir vector targeting RNF20 mRNA
(RHS4430-98486410) as well as a non-silencing shRNA
vector (RHS4346) were purchased from Open Biosys-
tems, Huntsville, AL, USA. C-terminally FLAG tagged
RNF20 was PCR cloned between the KpnI and EcoRV
sites of pcDNA3.0 (Invitrogen) using an RNF20 cDNA
as template (Open Biosystems, MHS4426-98361130).
Transfection of 2fTGH cells was carried out using
Arrest-in reagent according to the manufacturer’s proto-
col (Open Biosystems). Puromycin was used to select
for stable shRNAmir cell lines and individual clones
were characterized according to their RNF20 protein
expression using western blotting.
Additional material
Additional file 1: Western blotting of histones acid extracted after
treatment with 5’-deoxy-5’-methyl-thioadenosine (MTA),
carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG132), and RNAi-
mediated knockdown of RNF20 and of phosphorylated signal
transducer and activator of transcription 1 (STAT1) during
interferon (IFN)g treatment. (a-d) Acid-extracted histones collected
from 2fTGH cells after various treatments were subjected to SDS-PAGE,
blotted on nitrocellulose and the indicated antibodies were used to
develop the blots. (a, b) MTA (1.5 mM for 24 h), dimethylsulfoxide
(DMSO) (vehicle for MTA, for 24 h). (c) 2fTGH cell lines stably expressing
pGIPZ small hairpin RNA (shRNA)-RNF20 (RNF20), a non-silencing shRNA
vector (NS) and cells not transfected (NT). shRNA-RNF20, 65% loss of total
ubH2B. (d) MG132 (50 mM, for 4 h) produced a 95% loss of ubH2B
compared to ethanol (vehicle for MG132, for 4 h). (e) Whole cell extracts
of 2fTGH cells uninduced or induced with IFNg for 30 min and returned
to normal growth media were subjected to SDS-PAGE, blotted on
nitrocellulose and a phosphotyrosine 701 STAT1 antibody was used to
develop the blots. Upper band: STAT1a (91 kDa); lower band: STAT1b (84
kDa).
Additional file 2: Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG132)
treatment decreases inducible H2B monoubiquitination, affecting
H3K4 methylation but not H3K36 methylation. (a-d) Chromatin
immunoprecipitation (ChIP), using the indicated antibodies, of 2fTGH
cells treated with MG132 (in ethanol, 50 mM) for 4 h or carrier and then
induced with interferon (IFN)g for 30 min.
Additional file 3: 5,6-Dichlorobenzimidazole riboside (DRB)
inhibition of transcription elongation prevents dynamic ubH2B,
H3K4me3 and H3K36me3 during interferon regulatory factor 1
gene (IRF1) induction. (a) 2fTGH cells were treated with DRB (in
ethanol, 25 mg/ml) for 10 min prior to induction with interferon (IFN)g.
Cells were collected and RT Q-PCR was performed to quantitate IRF1
expression relative to GAPDH and presented as fold change upon
induction. Error bars represent standard error (n = 2). *P = 0.05. (b-d)
2fTGH cells were treated with DRB for 10 min prior to induction with
IFNg. ChIP assays with ubH2B, H3K4me3 and H3K36me3 antibodies were
performed and real-time quantitative PCR (Q-PCR) quantified the
precipitate yield, reported as percentage of input.
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